欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2010, Vol. 15 ›› Issue (12): 1353-1357.

• 基础研究 • 上一篇    下一篇

基于特异性结合多肽ZS-1的肺癌新肿瘤标志物的筛选

王素军1, 潘雪刁1, 臧林泉1, 王桂香1, 石磊1, 谢海棠2   

  1. 1广东药学院药科学院药理系, 广州 510006,广东;
    2皖南医学院弋矶山医院,安徽省药物临床评价中心,芜湖 241001,安徽
  • 收稿日期:2010-07-14 修回日期:2010-08-12 出版日期:2010-12-26 发布日期:2020-09-16
  • 通讯作者: 臧林泉,男,博士,教授,硕士生导师,研究方向:肿瘤药理学。Tel: 020-39352561 E-mail: zanglq@yahoo.com
  • 作者简介:王素军, 男, 博士, 副教授,研究方向: 药理学。Tel: 020-39352561 E-mail: wsj7272@126.com
  • 基金资助:
    广东药学院博士启动基金(2007YKX03);广东省医学科学技术研究基金(A2009317);广东省自然科学基金(9152402301000007);国家自然科学基金(81073141)

Screening of tumor mark for the lung cancer by using peptide ZS-1

WANG Su-jun1, PAN Xue-diao1, ZANG Lin-quan1, WANG Gui-xiang1, SHI Lei1, XIE Hai-tang2   

  1. 1Department of Pharmacology,Guangdong Pharmacy University,Guangzhou 510006,Guangdong,China;
    2Anhui Provincial Center for Drug Clinical Evaluation & Wuhu Yijishan Hospital, Wuhu 241001, Anhui, China
  • Received:2010-07-14 Revised:2010-08-12 Online:2010-12-26 Published:2020-09-16

摘要: 目的: 利用本实验室已获得的与肺癌特异性结合的十二肽ZS-1(EHMALTYPFRPP)从人类肺癌cDNA文库中筛选出肺癌相关标志物,并进行初步确认,为肺癌的临床早期诊断和靶向治疗奠定基础。方法: 本实验以ZS-1为探针,通过将偶联生物素的多肽ZS-1固化在亲和素处理的酶标板,筛选人类肺癌cDNA噬菌体展示文库,经过三轮减性筛选后,挑取与ZS-1特异性结合的噬菌体单克隆、扩增、纯化,再通过PCR技术扩增、产物纯化后,进行DNA测序,测序结果经过生物信息学分析, 随后采用组织芯片技术对相关生物大分子进行了检测。结果: 通过生物信息学分析首次发现与ZS-1结合的肺癌细胞膜受体蛋白为KIAA1199,随后以KIAA199抗体检测人肺癌组织芯片证实,KIAA1199的阳性检出率为 32.8%。结论: 从人类肺癌cDNA噬菌体展示文库中筛选出潜在的肺癌肿瘤标志物KIAA1199,为肺癌的早期诊治奠定基础。

关键词: 多肽ZS-1, cDNA文库, 减性筛选, 肺癌, 肿瘤标志物

Abstract: AIM: To select a potential biomarker for early lung cancer diagnosis and targeted therapy by using the cancer specific bounded peptide ZS-1 which had already been obtained from the laboratory.METHODS: The peptide ZS-1 marked by biotin was used as a probe to pan out the human lung cancer cDNA phage display library,after 3 rounds of subtraction panning,the specific binding clones of ZS-1 were identified.After amplification and purification,then those DNA sequences were identified and analyzed with bioinformatics. Tissue microarray technology was used to detect biomelecule in tissues.RESULTS: The lung cancer membrane receptor protein KIAA1199 binding ZS-1 was first found by bioinformatics analysis. Subsequently, a specific human lung cancer tissue microarray was detected and analysed by KIAA199 antibody.The results displayed KIAA1199 positive detection rate was 32.8%.CONCLUSION: A tumor biomarker KIAA1199 selected from human lung cancer cDNA library provides a potential tool for early lung cancer diagnosis and therapy.

Key words: Peptide ZS-1, cDNA library, Subtract bio-panning, Lung cancer, Tumor markers

中图分类号: